rheumatoid artheritis
Reading Document
Medical Text Search
rheumatoid arthritis pathophysiology clinical features diagnosis criteria
Medical Text Search
rheumatoid arthritis management treatment DMARDs biologics
GradeResponse
GradeResponse
Rheumatoid Arthritis (RA)
Overview
Rheumatoid arthritis is a chronic, systemic autoimmune inflammatory disease characterized by symmetric polyarthritis, synovial inflammation, and progressive joint destruction. Left untreated, it leads to significant disability and increased cardiovascular mortality.
Pathophysiology
RA involves a complex interplay of genetic and environmental triggers:
- Genetic susceptibility: HLA-DR4 and HLA-DR1 alleles (shared epitope hypothesis) confer risk
- Triggering events: smoking, infections, gut microbiome dysbiosis
- Key mechanism: Activation of autoreactive T cells and B cells leads to synovial inflammation. B cells produce rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA/anti-CCP)
- Cytokine cascade: TNF-α, IL-1, IL-6, and IL-17 drive synovial hyperplasia (pannus formation), which erodes cartilage and bone
- Pannus: Invasive, granulation-like tissue that destroys adjacent bone and cartilage at the joint margins
Clinical Features
Articular
| Feature | Details |
|---|---|
| Distribution | Symmetric, small joints (MCPs, PIPs, wrists, MTPs) |
| Morning stiffness | >1 hour — a hallmark finding |
| Sparing | DIPs typically spared (distinguishes from OA) |
| Deformities (late) | Ulnar deviation, swan neck, boutonnière, Z-thumb |
| Cervical spine | C1-C2 instability (atlantoaxial subluxation) — critical |
Extra-articular (more common with high disease burden)
- Skin: Rheumatoid nodules (subcutaneous, over pressure points)
- Pulmonary: Interstitial lung disease, pleuritis, nodules
- Cardiovascular: Accelerated atherosclerosis, pericarditis
- Eyes: Scleritis, episcleritis, keratoconjunctivitis sicca
- Hematologic: Anemia of chronic disease; Felty syndrome (RA + splenomegaly + neutropenia)
- Vasculitis: Rare, but serious when present
Diagnosis
2010 ACR/EULAR Classification Criteria (Harrison's, p. 10039)
Points are summed; ≥6/10 = definite RA:
| Domain | Score |
|---|---|
| Joint involvement | |
| 1 large joint | 0 |
| 2–10 large joints | 1 |
| 1–3 small joints | 2 |
| 4–10 small joints | 3 |
| >10 joints (including ≥1 small) | 5 |
| Serology | |
| Negative RF and anti-CCP | 0 |
| Low-positive RF or anti-CCP | 2 |
| High-positive RF or anti-CCP | 3 |
| Acute phase reactants | |
| Normal CRP and ESR | 0 |
| Abnormal CRP or ESR | 1 |
| Duration of symptoms | |
| <6 weeks | 0 |
| ≥6 weeks | 1 |
Key Investigations
- Serology: RF, anti-CCP (anti-CCP is more specific ~95%), ANA
- Inflammatory markers: ESR, CRP
- CBC: Normocytic anemia, thrombocytosis in active disease
- Imaging: X-rays (periarticular osteopenia, joint space narrowing, erosions); MRI/US for early erosions
Management
Treatment Goals
- Achieve treat-to-target (T2T): remission or low disease activity
- Prevent structural damage and preserve function
- Monitor with DAS28 or CDAI scores
Pharmacologic Therapy (Pharmacological Management of Inflammatory Arthritis, p. 63)
1. Conventional synthetic DMARDs (csDMARDs) — First-line
- Methotrexate (MTX): anchor drug; weekly dosing; requires folate supplementation; monitor LFTs and CBC
- Sulfasalazine
- Hydroxychloroquine (often combined — "triple therapy")
- Leflunomide
2. Biologic DMARDs (bDMARDs) — Used when csDMARDs inadequate
| Class | Examples |
|---|---|
| TNF inhibitors | Etanercept, adalimumab, infliximab, certolizumab, golimumab |
| IL-6 inhibitors | Tocilizumab, sarilumab |
| T-cell costimulation blocker | Abatacept |
| B-cell depletion | Rituximab |
| IL-1 inhibitor | Anakinra |
3. Targeted synthetic DMARDs (tsDMARDs)
- JAK inhibitors: Tofacitinib, baricitinib, upadacitinib
- Effective orally; used when biologics fail or are contraindicated
- Note: FDA black box warnings for JAK inhibitors (VTE, MACE, malignancy risk in higher-risk patients)
4. Adjunct therapies
- NSAIDs: Symptom relief only; no disease modification
- Glucocorticoids: Bridge therapy during DMARD initiation or flares; avoid long-term use
- Physical/occupational therapy
Monitoring
- MTX: LFTs, CBC, renal function every 1–3 months
- Biologics: TB screening before initiation; avoid in active infection; live vaccines contraindicated
- Disease activity: Reassess every 1–3 months until target achieved
Complications
- Joint destruction → disability
- Atlantoaxial subluxation → cord compression (pre-op screening mandatory)
- Cardiovascular disease (leading cause of excess mortality)
- Osteoporosis (disease + glucocorticoid use)
- Drug toxicity (MTX-related hepatotoxicity, pulmonary toxicity; biologic-related opportunistic infections)
Prognosis
Poor prognostic factors:
- High-positive anti-CCP or RF
- Early erosive disease
- Elevated CRP/ESR
- Extra-articular manifestations
- Functional limitation at presentation
With modern treat-to-target strategies, remission is achievable in a significant proportion of patients, particularly when treatment is initiated early.
Clinical pearl: Anti-CCP antibodies can be present years before clinical onset of RA and are highly specific (~95%). Early diagnosis and aggressive DMARD therapy meaningfully alter the disease course.
which nsaid is best
Medical Text Search
NSAIDs comparison rheumatoid arthritis efficacy safety selection
GradeResponse
No specific NSAID is definitively "best" for RA — they are considered therapeutically equivalent in efficacy at appropriate doses. The choice is driven by the patient's risk profile, not superiority of one drug over another.
NSAID Selection in RA
Efficacy
All NSAIDs work by inhibiting COX-1 and/or COX-2, reducing prostaglandin synthesis. Head-to-head trials show no meaningful difference in anti-inflammatory efficacy across NSAIDs at equipotent doses. They provide symptomatic relief only — no disease modification.
Choosing Based on Risk Profile
| Patient Profile | Preferred NSAID | Rationale |
|---|---|---|
| Low GI + low CV risk | Ibuprofen, naproxen, diclofenac | Widely used, well-tolerated |
| High GI risk (elderly, PUD history, steroids) | Celecoxib (COX-2 selective) ± PPI | Significantly lower GI bleeding risk vs. non-selective NSAIDs |
| High CV risk (hypertension, CAD, heart failure) | Naproxen | Most cardiovascular-neutral among NSAIDs; avoid COX-2 inhibitors |
| Renal impairment | Avoid all NSAIDs if possible | All NSAIDs reduce renal perfusion; use lowest dose for shortest duration |
| Elderly patients | Lowest effective dose, short duration; avoid indomethacin | Indomethacin has high CNS toxicity in elderly |
Key Points on Specific Agents
- Naproxen (500 mg BD): Longest half-life, twice-daily dosing, most CV-neutral — often preferred when CV risk is a concern
- Ibuprofen (400–800 mg TDS): Most widely used; GI-safer than indomethacin; competes with aspirin binding (relevant if patient is on low-dose aspirin)
- Diclofenac (75 mg BD): Modest COX-2 selectivity; moderate GI risk; higher hepatotoxicity risk — monitor LFTs
- Celecoxib (200 mg OD/BD): Best GI safety profile; higher CV risk (contraindicated post-MI, heart failure); no interaction with aspirin
- Indomethacin (25–50 mg TDS): Potent and effective but highest rate of CNS side effects (headache, dizziness, confusion) and GI toxicity — generally avoided as first choice
Practical Bottom Line
- For most RA patients: naproxen + PPI is a reasonable default (good efficacy, CV safety, manageable GI risk with PPI cover)
- For high GI risk: celecoxib (provided no significant CV disease)
- For high CV risk: naproxen at the lowest effective dose
- Always co-prescribe a PPI with any non-selective NSAID in RA patients (many are also on corticosteroids, compounding GI risk)
- Remember: NSAIDs are adjunct symptom relief in RA — DMARDs remain the essential therapy
This is a shared conversation. Sign in to Orris to start your own chat.